4.1.4.2.2.2. summary evidence recommendation beta-3 agonists. summary evidencelemirabegron vibegron better placebo improvement oab/uui symptoms.1aadverse event rates mirabegron vibegron similar placebo.1abeta-3 agonists effective antimuscarinics management oab lower dry mouth rates.1apatients inadequately treated solifenacin 5 mg may benefit addition mirabegron rather dose escalation solifenacin.1b recommendationsstrength ratingoffer beta-3 agonists alternative anticholinergics women oab fail conservative treatment.strongoffer mirabegron additional therapy patients inadequately treated solifenacin 5 mg.weak